Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

New Type 1 Diabetes Diagnostic Antigen Panel Now Available, Collaboration to Further Advance Panel

By BiotechDaily International staff writers
Posted on 17 Sep 2013
Image: The new multiplexed Type 1 Diabetes assay on Genalyte’s Maverick Detection System (Photo courtesy of Genalyte).
Image: The new multiplexed Type 1 Diabetes assay on Genalyte’s Maverick Detection System (Photo courtesy of Genalyte).
A new multiplexed, early diagnosis biomarker-panel assay that measures autoantigens associated with the development of Type 1 Diabetes is now available. A specially funded collaboration is also underway to further advance the assay.

The Maverick Type 1 Diabetes (T1D) Assay from Genalyte, Inc. (San Diego, CA, USA) is the first multiplexed assay that measures 7 autoantibodies associated with the destruction of pancreatic islet β cells seen in T1D. In addition, new preventative therapies may have the potential to reduce or stop this cell destruction in patients at risk—identifying these patients early would facilitate the development and use of these therapies.

The Maverick T1D Assay is a semiquantitative photonic ring immunoassay designed to simultaneously detect the antigens. The Maverick Detection System analyzes each antigen individually and reports results in less than 15 minutes, without the use of dyes, fluorescent probes, or radioactive labels. The assay requires only 2–5 μL serum or plasma sample and minimal hands-on time. It measures autoantibodies to insulin, proinsulin, glutamate decarboxylases GAD65 and GAD67, IA-2 (PTPRN, ICA512), phogrin (PTPRN2, IA-2ß) and ZnT8 (Zinc Transporter 8, SLC30A8).

The Maverick Detection System itself is based on Genalyte’s Microring Sensor Technology to reduce or eliminate sample preparation and provide scalable multiplexing for both proteins and nucleic acids. Its one-step workflow can rapidly deliver accurate results from small volume samples of many types. It has a large dynamic range and excellent sensitivity and reproducibility.

Genalyte is collaborating with the Barbara Davis Center for Childhood Diabetes (BDC; Aurora, CO, USA) at the University of Colorado School of Medicine to further develop and test panels for early detection of T1D. The current T1D panel was developed as part of the first phase of a Small Business Innovation Research grant awarded to Genalyte to develop multiplexed assays for early detection and monitoring of T1D. A USD 500,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases also supports expansion of the approach to allow autoantibody response profiling by multiple criteria to enhance the ability to detect and monitor disease development. “The pioneering work of Drs. George Eisenbarth and Liping Yu at BDC established assays for the measurement of islet autoantibodies. [...] The unique capabilities of our Maverick detection platform have the potential to provide researchers and clinicians with tools to detect and track this process from an early stage, when interventions to interrupt the disease process may be feasible,” said Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.

“We are pleased to offer our innovative T1D antigen panel to diabetes researchers worldwide at the same time that we are working with Dr. Liping Yu and his lab at the Barbara Davis Diabetes Center to expand the utility of the approach,” added Dr. Gleeson.

Maverick assays are currently available for research use only. Genalyte also offers a Custom Spotting Service for various proteins supplied by customers.

Related Links:

Barbara Davis Center for Childhood Diabetes



view channel
Image: Schematic representation of HIV DART binding to two distinct antigens simultaneously, redirecting the killer T-cells to destroy HIV-1 infected cells (Photo courtesy of Duke University).

Bi-Specific Antibodies Shown to Clear Latent HIV Infections

Bi-specific antibodies or DARTS (dual-affinity re-targeting proteins) have been used to eliminate latent HIV-infection from patient samples by redirecting polyclonal T-cells to specifically engage with... Read more

Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.